Impax Laboratories Inc. (IPXL)

17.90
0.22 1.24
NYSE : Health Technology
Prev Close 17.68
Open 17.72
Day Low/High 17.50 / 18.29
52 Wk Low/High 13.47 / 18.29
Volume 839.29K
Avg Volume 916.90K
Exchange NYSE
Shares Outstanding 73.87M
Market Cap 1.35B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
The 5 Dumbest Things on Wall Street This Week: March 8

The 5 Dumbest Things on Wall Street This Week: March 8

Ron Johnson, Perpetual Dumbest Thing, returns, along with Sohu and Groupon's Andrew Mason.

Finkelstein Thompson LLP Announces Investigation Of Impax Laboratories, Inc.

Finkelstein Thompson LLP Announces Investigation Of Impax Laboratories, Inc.

The law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of the drug manufacturer Impax Laboratories, Inc.

4 Stocks Spiking on Unusual Volume

4 Stocks Spiking on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By Impax Laboratories Inc.

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By Impax Laboratories Inc.

Levi & Korsinsky is investigating potential claims on behalf of purchasers of Impax Laboratories Inc.

Abraham, Fruchter & Twersky, LLP Announces Investigation Of Impax Laboratories, Inc.

Abraham, Fruchter & Twersky, LLP Announces Investigation Of Impax Laboratories, Inc.

Abraham, Fruchter & Twersky, LLP has commenced an investigation concerning possible violations of federal securities laws by Impax Laboratories, Inc.

Dow Closes at Record High

Dow Closes at Record High

Major U.S. stock averages saw strong momentum Tuesday, with the Dow recording an all-time closing high.

Dow Poised to Pass All-Time High

Dow Poised to Pass All-Time High

Stock futures are pointing to a higher open on Wall Street Tuesday, looking to extend the prior session's gains.

Impax Provides An Update On FDA Inspection Of Hayward Facility

Impax Provides An Update On FDA Inspection Of Hayward Facility

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.

Impax Laboratories To Present At The Cowen & Company 33rd Annual Health Care Conference

Impax Laboratories To Present At The Cowen & Company 33rd Annual Health Care Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Cowen & Company 33 rd Annual Health Care Conference on Wednesday, March 6, at 8:00 a.

Impax Laboratories Reports Fourth Quarter And Full Year 2012 Results

Impax Laboratories Reports Fourth Quarter And Full Year 2012 Results

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported fourth quarter 2012 adjusted net income of $20.

Impax And Shire Settle Litigation Concerning Supply Of Authorized Generic Adderall XR®

Impax And Shire Settle Litigation Concerning Supply Of Authorized Generic Adderall XR®

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc.

Http://www.impaxlabs.com

Http://www.impaxlabs.com

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today that the U.

Impax Laboratories Launches Oxymorphone Hydrochloride Extended-Release Tablets

Impax Laboratories Launches Oxymorphone Hydrochloride Extended-Release Tablets

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it is commencing shipment of Oxymorphone Hydrochloride Extended-Release Tablets, through Global Pharmaceuticals, Impax’s generics division.

Impax Laboratories To Present At The 31st Annual J.P. Morgan Healthcare Conference

Impax Laboratories To Present At The 31st Annual J.P. Morgan Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the 31 st Annual J.

Impax Laboratories Names Bryan M. Reasons As Chief Financial Officer

Impax Laboratories Names Bryan M. Reasons As Chief Financial Officer

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that Bryan M.

Http://www.perrigo.com

Http://www.perrigo.com

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug...

Impax Laboratories To Present At The Piper Jaffray 24th Annual Healthcare Conference

Impax Laboratories To Present At The Piper Jaffray 24th Annual Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Piper Jaffray 24 th Annual Healthcare Conference on Tuesday, November 27, at 8:00 a.

First 90 Days of 2013 Are Live or Die For These Biotech Stocks

First 90 Days of 2013 Are Live or Die For These Biotech Stocks

Clinical trials, drug launches and FDA approval decisions fill the early 2013 biotech calendar.

Impax Laboratories And ThoRx Laboratories Confirm Patent Challenge Relating To Generic OPANA® ER 5 Mg, 7.5 Mg, 10 Mg, 15 Mg, 20 Mg, 30 Mg, And 40 Mg

Impax Laboratories And ThoRx Laboratories Confirm Patent Challenge Relating To Generic OPANA® ER 5 Mg, 7.5 Mg, 10 Mg, 15 Mg, 20 Mg, 30 Mg, And 40 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) and its wholly owned subsidiary, ThoRx Laboratories, Inc.

Impax Laboratories To Present At The Credit Suisse 2012 Healthcare Conference

Impax Laboratories To Present At The Credit Suisse 2012 Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Credit Suisse 2012 Healthcare Conference on Wednesday, November 14, at 1:00 p.

Impax Laboratories Reports Third Quarter 2012 Results

Impax Laboratories Reports Third Quarter 2012 Results

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported third quarter 2012 financial results.

Http://www.impaxlabs.com

Http://www.impaxlabs.com

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Laboratories Announces Time Change For Third Quarter 2012 Earnings Conference Call On October 30

Impax Laboratories Announces Time Change For Third Quarter 2012 Earnings Conference Call On October 30

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its third quarter 2012 conference call and live webcast with financial analysts on Tuesday October 30, 2012 will now be held at 12:00 p.

Impax Laboratories Schedules Conference Call And Webcast For Third Quarter 2012 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Third Quarter 2012 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its third quarter 2012 financial results will be released before the market opens on Tuesday, October 30, 2012 and will be available on Impax’s Web ...

Analysts' Actions: FB HPQ MAR GPS ZNGA

Analysts' Actions: FB HPQ MAR GPS ZNGA

Here are today's top research calls.

8 Stocks Rising on Big Volume

8 Stocks Rising on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Impax Laboratories To Present At The UBS Global Life Sciences Conference

Impax Laboratories To Present At The UBS Global Life Sciences Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Life Sciences Conference on Thursday, September 20, at 4:30 p.

Impax Laboratories Announces Settlement Of Litigation Relating To CONCERTA®

Impax Laboratories Announces Settlement Of Litigation Relating To CONCERTA®

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it and Teva Pharmaceuticals USA, Inc.

Impax Laboratories Announces Settlement Of Litigation Relating To RENVELA® And RENAGEL®

Impax Laboratories Announces Settlement Of Litigation Relating To RENVELA® And RENAGEL®

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has reached agreement with Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), to settle pending U.